- Home
- TYRA vs RDVT Comparison
TYRA vs RDVT Comparison
Compare TYRA & RDVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- RDVT
- Stock Information
- Founded
- TYRA 2018
- RDVT 2017
- Country
- TYRA United States
- RDVT United States
- Employees
- TYRA 38
- RDVT N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- RDVT Computer Software: Prepackaged Software
- Sector
- TYRA Health Care
- RDVT Technology
- Exchange
- TYRA Nasdaq
- RDVT Nasdaq
- Market Cap
- TYRA 666.4M
- RDVT 550.8M
- IPO Year
- TYRA 2021
- RDVT N/A
- Fundamental
- Price
- TYRA $13.17
- RDVT $38.84
- Analyst Decision
- TYRA Strong Buy
- RDVT Strong Buy
- Analyst Count
- TYRA 6
- RDVT 1
- Target Price
- TYRA $30.50
- RDVT $25.00
- AVG Volume (30 Days)
- TYRA 247.2K
- RDVT 104.8K
- Earning Date
- TYRA 03-18-2025
- RDVT 02-27-2025
- Dividend Yield
- TYRA N/A
- RDVT 0.77%
- EPS Growth
- TYRA N/A
- RDVT N/A
- EPS
- TYRA N/A
- RDVT 0.36
- Revenue
- TYRA N/A
- RDVT $70,685,000.00
- Revenue This Year
- TYRA N/A
- RDVT $24.88
- Revenue Next Year
- TYRA N/A
- RDVT $14.52
- P/E Ratio
- TYRA N/A
- RDVT $109.49
- Revenue Growth
- TYRA N/A
- RDVT 21.43
- 52 Week Low
- TYRA $11.89
- RDVT $16.56
- 52 Week High
- TYRA $29.60
- RDVT $43.44
- Technical
- Relative Strength Index (RSI)
- TYRA 43.64
- RDVT 50.72
- Support Level
- TYRA $12.27
- RDVT $38.57
- Resistance Level
- TYRA $13.79
- RDVT $41.80
- Average True Range (ATR)
- TYRA 0.71
- RDVT 1.90
- MACD
- TYRA 0.03
- RDVT -0.04
- Stochastic Oscillator
- TYRA 51.09
- RDVT 41.92
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in big data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses, and assets.